Key Drivers and Opportunities in the Cutaneous Squamous Cell Carcinoma (CSCC) Market: Insights into Trends and Growth
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
What Long-Term Growth Rate is Expected for the Cutaneous Squamous Cell Carcinoma (CSCC) Market Between 2025 and 2034?
The market size for cutaneous squamous cell carcinoma (cSCC) has seen robust growth recently and is projected to expand from $7.45 billion in 2024 to $7.90 billion in 2025, with a compound annual growth rate (CAGR) of 6.1%. The considerable growth during the past years can be due to factors such as the increase in non-melanoma skin cancer cases, an expanding aging populace, more exposure to ultraviolet rays, advances in healthcare infrastructure, and the increased adoption of immunotherapy in cancer treatment.
The market for cutaneous squamous cell carcinoma (cSCC) is projected to experience robust growth in the coming years, soaring to $9.90 billion by 2029 with a compound annual growth rate (CAGR) of 5.8%. The predicted growth during the forecast period can be tied to the increasing prevalence of targeted therapies, heightened consciousness regarding skin cancer prevention, a rise in medical tourism specifically for cancer treatments, the growing preference for minimally invasive surgeries, and supportive government programs for cancer care. Predicted trends for the forecast period encompass advancements in the field of dermatology diagnostics, the creation of sophisticated radiotherapy techniques, technological progression in dermatology, ground-breaking developments in immunotherapy treatments, and enhancements in photodynamic therapy.
Which Major Market Drivers Are Expected to Boost the Cutaneous Squamous Cell Carcinoma (CSCC) Market’s Growth Potential?
Projected growth in the cutaneous squamous cell carcinoma (cSCC) market is linked to a rising understanding of skin cancer. Skin cancer, characterized by atypical skin cell development usually from extensive UV exposure, can vary from benign to potentially lethal. The escalating consciousness surrounding skin cancer can be attributed to the proliferation of public health campaigns, easy access to relevant information, and amplified focus on preliminary detection and prevention, which subsequently drives up the demand for diagnostic and treatment methods. The role of cutaneous squamous cell carcinoma (cSCC) in championing skin cancer care is becoming increasingly important by paving the way for focused therapies, enhancing diagnostic processes and improving patient results, thereby facilitating superior disease control. For instance, data from the American Cancer Society, a US non-profit institution committed to fighting cancer, reveals a 3.2% rise in skin cancer cases from 108,270 in 2022 to 104,930 in 2023. As such, the burgeoning awareness of skin cancer is anticipated to spur growth in the cutaneous squamous cell carcinoma (cSCC) market.
Get Your Free Sample of the Global Cutaneous Squamous Cell Carcinoma (CSCC) Market Report Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=21163&type=smp
What Are the Key Firms That Are Driving Transformation in the Cutaneous Squamous Cell Carcinoma (CSCC) Market?
Major companies operating in the cutaneous squamous cell carcinoma (CSCC) market are F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, Novartis AG, GSK plc, 3M Company, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Incyte Corporation, Hikma Pharmaceuticals plc, Shanghai Henlius Biotech Inc., Fortress Biotech Inc., Rakuten Medical Inc., Morphogenesis Inc., CureVac N.V., Vidac Pharma Inc.
What Current Trends in the Cutaneous Squamous Cell Carcinoma (CSCC) Market Should Industry Players Pay Attention To?
Major players in the cutaneous squamous cell carcinoma (cSCC) market are focusing on enhancing immuno-oncology therapies, including PD-L1 inhibitors and targeted therapies, with the aim to improve patient outcomes and offer effective treatments for advanced skin cancer. PD-L1, also known as programmed death-ligand 1, is a protein that hampers the immune response by binding with PD-1 receptors present on T-cells, thus assisting cancer cells in evading immune detection. For instance, in December 2024, the US-based biotech firm, Checkpoint Therapeutics Inc., garnered FDA approval for Unloxcyt (cosibelimab-ipdl). The groundbreaking aspect of Unloxcyt is its capacity to inhibit PD-L1, which bolsters the immune system’s potential to combat cancer, thereby providing a safer and more efficient treatment alternative. Moreover, its dual action mechanism presents a promising strategy for managing advanced cutaneous squamous cell carcinoma (cSCC). The sanction was grounded on outcomes from the CK-301-101 trial, which exhibited clinically significant objective response rates and sustained responses in patients with advanced cSCC.
Get Instant Access to the Global Cutaneous Squamous Cell Carcinoma (CSCC) Market Report with Swift Delivery!
How Are Market Segments in the Cutaneous Squamous Cell Carcinoma (CSCC) Industry Positioned for Long-Term Growth?
The cutaneous squamous cell carcinoma (CSCC) market covered in this report is segmented –
1) By Treatment: Surgical Treatment, Non-Surgical Treatment
2) By Diagnosis: Computed Tomography (CT), Magnetic Resonance Imaging (MRI), Biopsy
3) By Application: Hospitals, Cancer Institutes, Ambulatory Surgical Centers, Other Applications
Subsegments:
1) By Surgical Treatment: Excisional Surgery, Mohs Micrographic Surgery, Curettage And Electrodessication
2) By Non-Surgical Treatment: Radiation Therapy, Cryotherapy, Photodynamic Therapy, Topical Therapies, Systemic Therapies
What Regions Are Driving Expansion in the Cutaneous Squamous Cell Carcinoma (CSCC) Market?
North America was the largest region in the cutaneous squamous cell carcinoma (CSCC) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cutaneous squamous cell carcinoma (CSCC) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Key Parameters Define the Cutaneous Squamous Cell Carcinoma (CSCC) Market’s Scope?
Cutaneous squamous cell carcinoma (cSCC) is a type of skin cancer that develops in the squamous cells of the skin’s outer layer. It typically occurs in sun-exposed areas and can range from localized lesions to more aggressive forms that may spread to other parts of the body.
Browse Through More Similar Reports By The Business Research Company:
Chromatin immunoprecipitation (ChIP) Sequencing Global Market Report 2025
Autoimmune Disease Diagnosis Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/autoimmune-disease-diagnosis-global-market-report
Cyclic Heavy Menstrual Bleeding Global Market Report 2025
https://thebusinessresearchcompany.com/report/cyclic-heavy-menstrual-bleeding-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
